Revelation Capital Management
Latest statistics and disclosures from Revelation Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Singular Genomics Systems In, AKLI, NPCE, and represent 100.00% of Revelation Capital Management's stock portfolio.
- Added to shares of these 1 stock: AKLI.
- Started 1 new stock position in AKLI.
- Reduced shares in these 2 stocks: NPCE, ACCD.
- Sold out of its position in ACCD.
- Revelation Capital Management was a net seller of stock by $-643k.
- Revelation Capital Management has $4.3M in assets under management (AUM), dropping by -39.76%.
- Central Index Key (CIK): 0001801811
Tip: Access up to 7 years of quarterly data
Positions held by Revelation Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Revelation Capital Management
Revelation Capital Management holds 3 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Singular Genomics Systems In | 83.2 | $3.5M | 1.4M | 2.50 |
|
|
| Akili (AKLI) | 13.1 | $556k | NEW | 246k | 2.26 |
|
| Neuropace (NPCE) | 3.8 | $161k | -82% | 43k | 3.75 |
|
Past Filings by Revelation Capital Management
SEC 13F filings are viewable for Revelation Capital Management going back to 2021
- Revelation Capital Management 2022 Q3 filed Nov. 7, 2022
- Revelation Capital Management 2022 Q2 filed Aug. 15, 2022
- Revelation Capital Management 2022 Q1 filed May 12, 2022
- Revelation Capital Management 2021 Q4 filed Feb. 14, 2022